吉非替尼
医学
埃罗替尼
肺癌
临床终点
肿瘤科
表皮生长因子受体
表皮生长因子受体抑制剂
随机对照试验
内科学
癌症
作者
Ping Peng,Juejun Gong,Yujie Zhang,Shuchang Zhou,Yichen Li,Guang Han,Rui Meng,Yongshun Chen,Ming Yang,Qian Shen,Qian Chu,Xia Shu,Peng Zhang,Lu Zhang,Yuan Chen,Li Zhang
标识
DOI:10.1016/j.radonc.2023.109681
摘要
The addition of SBRT significantly delayed the onset of acquired resistance to EGFR-TKIs and prolonged the PFS and OS of patients. Radiotherapy of the primary lesion alone might be superior to metastatic sites. Further confirmatory studies are needed to confirm our findings.
科研通智能强力驱动
Strongly Powered by AbleSci AI